MedTrace Logo

CardiAQ-Edwards™ Transcatheter Mitral Valve Replacement (TMVR) Study

NCT02722551 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2018-01-09

No results posted yet for this study

Summary

Clinical study to evaluate the safety and performance of the CardiAQ-Edwards™ Transcatheter Mitral Valve

Conditions

  • Mitral Valve Regurgitation

Interventions

DEVICE

Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve

Replacement of the mitral valve through a transcatheter approach

Sponsors & Collaborators

  • Edwards Lifesciences

    lead INDUSTRY

Principal Investigators

  • Lars Sondergaard · The Rigshospitalet, Copenhagen, Denmark

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-11-30
Primary Completion
2019-10-31
Completion
2024-10-31

Countries

  • Canada
  • Denmark
  • France
  • Germany
  • Italy
  • Netherlands
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02722551 on ClinicalTrials.gov